Which loses more weight, Wegovy or Zepbound?

Tirzepatide (Zepbound) showed a larger average reduction (up to ~20.9% in SURMOUNT-1) than semaglutide (Wegovy, ~14.9% in STEP 1), but they were not compared head-to-head for weight. A clinician weighs the trade-offs for your situation.

Does Zepbound affect birth control but Wegovy does not?

Yes. The tirzepatide label warns Zepbound may reduce oral-contraceptive effectiveness and advises a backup method for 4 weeks after starting and after dose increases. The semaglutide label for Wegovy does not carry that warning.

Are Wegovy and Zepbound the same as Ozempic and Mounjaro?

They share molecules: Wegovy and Ozempic are both semaglutide, and Zepbound and Mounjaro are both tirzepatide. Wegovy and Zepbound are the weight-approved brands; Ozempic and Mounjaro are approved for type 2 diabetes.

Head-to-head comparisons

Wegovy vs Zepbound for Women: Which Is Better?

Medically reviewed by Editorial Medical Review, MD, NAMS-CMP · Updated July 2026

Quick answer

Wegovy (semaglutide) and Zepbound (tirzepatide) are both FDA-approved for chronic weight management. In separate trials, semaglutide produced about 14.9% mean weight loss and tirzepatide up to about 20.9%. For women, the biggest label difference is that Zepbound may lower oral birth-control effectiveness, while Wegovy carries no such warning.

Same goal, two different molecules

Wegovy is semaglutide 2.4 mg, a GLP-1 receptor agonist. Zepbound is tirzepatide, which activates both GIP and GLP-1 receptors. Both are once-weekly injections approved for adults with obesity, or overweight plus a weight-related condition.

For the FDA-verbatim efficacy and safety numbers side by side, see the clinical comparison of semaglutide vs tirzepatide rather than relying on a single headline figure. This guide focuses on the women-specific decision points those tables do not cover.

The birth-control difference matters

The tirzepatide label warns that Zepbound may reduce the effectiveness of oral hormonal contraceptives and advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase. The semaglutide label does not carry this warning.

If reliable oral contraception is a priority, this is the clearest practical distinction between the two, and one to raise directly with a prescribing clinician.

Trial magnitude, tolerability, and cost

Tirzepatide showed a larger average weight reduction across its trials than semaglutide did in its own, though the two were not tested head-to-head for weight in a single study. Both most commonly cause gastrointestinal side effects that ease as the dose is escalated slowly.

Both weight loss and, in PCOS, the return of ovulation can happen on either drug, so reliable contraception matters when pregnancy is not intended. Cost is similar in range; the cited figures below and the linked cost guides give current numbers.

Key points

Both Wegovy and Zepbound are FDA-approved for weight; Ozempic and Mounjaro are the diabetes versions.
Semaglutide ~14.9% (STEP 1) vs tirzepatide up to ~20.9% (SURMOUNT-1), in separate trials.
Zepbound may lower oral birth-control effectiveness; Wegovy carries no such warning.
See the clinical comparison table for the side-by-side efficacy and safety figures.

Molecule facts (canonical explainers)

This is a decision guide. For the plain-fact explainer of each molecule (mechanism, FDA status, dosing cautions), see:

Wegovy for women — GLP-1 receptor agonist (semaglutide 2.4 mg)
Zepbound for women — GIP/GLP-1 receptor dual agonist (tirzepatide)

Providers we review in this area

Editorial reviews only — not treatment recommendations. Prescribing decisions rest with a licensed clinician. For the full directory, see all GLP-1 for women providers.

Form Health — Board-certified obesity medicine physicians prescribing GLP-1s. Often insurance-covered — among the most affordable options when insurance applies.
Mochi Health — Doctor-led GLP-1 weight loss program. Offers compounded semaglutide/tirzepatide and FDA-approved Wegovy/Zepbound for eligible patients.
Plushcare GLP-1 — Primary care telehealth that prescribes Wegovy and Zepbound when clinically appropriate. Insurance-friendly.

Cost

Wegovy self-pay is about $499 per month via NovoCare; Zepbound self-pay vials run about $349 to $599 via LillyDirect. Verify current pricing before acting.

See the full cost breakdown in our How much does Wegovy cost?.

Frequently asked questions

Which loses more weight, Wegovy or Zepbound?: Tirzepatide (Zepbound) showed a larger average reduction (up to ~20.9% in SURMOUNT-1) than semaglutide (Wegovy, ~14.9% in STEP 1), but they were not compared head-to-head for weight. A clinician weighs the trade-offs for your situation.
Does Zepbound affect birth control but Wegovy does not?: Yes. The tirzepatide label warns Zepbound may reduce oral-contraceptive effectiveness and advises a backup method for 4 weeks after starting and after dose increases. The semaglutide label for Wegovy does not carry that warning.
Are Wegovy and Zepbound the same as Ozempic and Mounjaro?: They share molecules: Wegovy and Ozempic are both semaglutide, and Zepbound and Mounjaro are both tirzepatide. Wegovy and Zepbound are the weight-approved brands; Ozempic and Mounjaro are approved for type 2 diabetes.

Sources

Every efficacy, safety, and price claim above resolves to an FDA label, published trial, guideline, or manufacturer / GoodRx pricing page. External links open in a new tab.

Keep reading

ClearHormones updates these guides as FDA status and pricing change. Verify current approval status and pricing on the manufacturer or FDA page before acting.